Company: IMNN
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001641172-25-013088
Chunk: 7

Company: Imunon, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 7
---
 exercised in full. The Common Warrants will be exercisable upon receipt of such approval as may be required by the applicable rules and regulations of Nasdaq (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Common Warrants and the shares of Common Stock upon the exercise thereof (“ Stockholder Approval,” and such date, the “ Stockholder Approval Date”) and have a term of three years from the Stockholder Approval Date. The Company agreed to hold a stockholder meeting on or prior to August 25, 2025 for the purpose of obtaining Stockholder Approval and to file a proxy statement for such meeting by June 16, 2025 and to use the record date that was previously set on May 13, 2025 for the stockholder meeting to seek Stockholder Approval. If the Company does not obtain Stockholder Approval at the first meeting, the Company will call a meeting every 90 days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the Common Warrants are no longer outstanding. In the event that we are unable to obtain the required Stockholder Approval for the Common Warrants, such warrants will not be exercisable and therefore have no value.

A holder of the Pre-Funded Warrants and the Common Warrants may not exercise any portion of such holder’s Pre-Funded Warrants or Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of the Company’s outstanding shares of Common Stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to the Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise.

| 2 |

In connection with the Private Placement, the Company entered into the Registration Rights Agreement, dated as of May 23, 2025, with the purchasers in the Private Placement, pursuant to which the Company agreed to prepare and file a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants and the Common Warrants.

H.C. Wainwright & Co., LLC acted as the Company’s lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent, in connection